# Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.

> **NCT06613113** · NA · RECRUITING · sponsor: **Ningbo Medical Center Lihuili Hospital** · enrollment: 30 (estimated)

## Conditions studied

- MSS Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT06613113
- **Lead sponsor:** Ningbo Medical Center Lihuili Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-07
- **Primary completion:** 2025-04-30
- **Final completion:** 2027-07-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613113, "Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06613113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*